ArticleCommunications biology2022
Macrophage Jak2 deficiency accelerates atherosclerosis through defects in cholesterol efflux.
Article in Communications biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Intestinal epithelial cell-specific deletion of Jak2 disrupts gut homeostasis.Scientific reports · 2026Article
- Prevalence of the JAK2 V617F Mutation in Patients with Non-Cardioembolic Stroke.Journal of atherosclerosis and thrombosis · 2026Article
- Common clonal hematopoiesis driver mutations have disparate effects on macrophage cytokines, clonal expansion, and atherogenesis.JCI insight · 2026Article
- Investigating Alternative Treatments for Dyslipidemia Using Bioactive Compounds Derived from Kiwifruit (Actinidia chinensis): A Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation Analysis.Current drug targets · 2026Article
- Article
- A genetic map of human metabolism across the allele frequency spectrum.Nature genetics · 2025Article
- Platelet Jak2 deficiency accelerates atherosclerosis with increased inflammatory response.The Journal of biological chemistry · 2025Article
- The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications.Signal transduction and targeted therapy · 2025Review
- Bacterial indole-3-propionic acid inhibits macrophage IL-1β production through targeting methionine metabolism.Science China. Life sciences · 2025Article
- Autophagy and Its Association with Macrophages in Clonal Hematopoiesis Leading to Atherosclerosis.International journal of molecular sciences · 2025Review
- Current understanding and management of cardiovascular involvement in rheumatic immune-mediated inflammatory diseases.Nature reviews. Rheumatology · 2024Review
- Cardiovascular Risk in Philadelphia-Negative Myeloproliferative Neoplasms: Mechanisms and Implications-A Narrative Review.Current issues in molecular biology · 2024Review
- Weighted Breaths: Exploring Biologic and Non-Biologic Therapies for Co-Existing Asthma and Obesity.Current allergy and asthma reports · 2024Review
- JAK2 V617F Mutation and Large Cerebral Artery Disease in Patients with Myeloproliferative Neoplasms.Journal of atherosclerosis and thrombosis · 2023Article
- Cardiovascular Disease in Myeloproliferative Neoplasms:JACC. CardioOncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 6 institutions in 3 countries.
Funding
Abstract
Atherosclerosis is a chronic inflammatory condition in which macrophages play a major role. Janus kinase 2 (JAK2) is a pivotal molecule in inflammatory and metabolic signaling, and Jak2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.